USA POTENTIALLY ANTI-COMPETITIVE PATENT SETTLEMENTS DWINDLE AFTER ACTAVIS CASE
February 1st, 2016
THE FEDERAL Trade Commission (FTC) of the USA has claimed that its tough action against paying generic manufacturers not to make copies of out-of-patent original medicine is having an effect. In a new report, it has argued that the number of such potentially anti-competitive deals filed with the FTC dropped to 21 in the 2014 financial year, from 29 in 2013 and 40 in 2012. This was before the US Supreme Court’s landmark antitrust decision in the ‘FTC v Actavis’ case in 2013, where judges ruled that a branded drug manufacturer’s reverse payment to a generic ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.